Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Key facts

Sponsor

M.D. Anderson Cancer Center

Principal Investigator

Renata Ferrarotto, MD

M.D. Anderson Cancer Center

Intervention

Carboplatin(drug)

Enrollment

28 target

Eligibility

18 years · All sexes

Timeline

2019 – 2026

Study locations (1)

• M D Anderson Cancer Center, Houston, Texas, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the larynx

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07209189
  Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• RECRUITINGNANCT06915454
  High-Resolution PET-CT Imaging for Surgical Margin Visualization
  Vanderbilt-Ingram Cancer Center
• RECRUITINGPHASE2NCT06831149
  Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
  Matthew Spector
• ACTIVE NOT RECRUITINGPHASE1NCT05540899
  Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
  American College of Radiology
• RECRUITINGPHASE2NCT06039631
  Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
  Fudan University
• RECRUITINGPHASE1NCT03114462
  Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
  M.D. Anderson Cancer Center

See all trials for Squamous cell carcinoma of the larynx →